Intravenous Immunoglobulin-based Adjuvant Therapy for Severe COVID-19: a Single-center Retrospective Cohort Study

Xiao Hou

Women and Children's Health Care Hospital: Shandong Maternal and Child Health Hospital

Li Tian

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Lei Zhou

Shandong Qianfuo Mountain Hospital: Shandong Qianfoshan Hospital

Xinhua Jia

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Li Kong

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Yitao Xue

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Hao Hao (✉ haohao0826@163.com)

Shandong University of Traditional Chinese Medicine Affiliated Hospital <https://orcid.org/0000-0003-4488-4840>

Xianqing Meng

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Feihu Zhang

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Xiaobin Dong

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Research

Keywords: SARS-CoV-2, COVID-19, IVIG, Mortality, Mechanical ventilation, Hospital length of stay

Posted Date: March 9th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-258587/v1>

License: (cc) (i) This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Objective Coronavirus disease 2019 (COVID-19) is a major challenge facing the world. Certain guidelines recommend intravenous immunoglobulin (IVIG) for adjuvant treatment of COVID-19. However, there is a lack of clinical evidence to support the use of IVIG.

Methods This single-center retrospective cohort study included all adult patients with laboratory-confirmed severe COVID-19 in the Respiratory and Critical Care Unit of Dabie Mountain Regional Medical Center, China. Patient information, including demographic data, laboratory indicators, the use of glucocorticoids and IVIG, hospital mortality, the application of mechanical ventilation, and the length of hospital stay was collected. The primary outcome was the composite end point, including death and the use of mechanical ventilation. The secondary outcome was the length of hospital stay.

Results Of the 285 patients with confirmed COVID-19, 113 severely ill patients were included in this study. Compared with the non-IVIG group, more patients in the IVIG group reached the composite end point [12 (25.5%) vs 5 (7.6%), $P=0.008$]. However, there was no statistically significant difference in the primary outcome between the two groups ($P=0.167$) after adjusting for confounding factors. Patients in the IVIG group had a longer hospital stay [23.0 (19.0-31.0) vs 16.0 (13.8-22.0), $P<0.001$]. After adjusting for confounding factors, there was still a statistically significant difference between the two groups ($P=0.041$).

Conclusion Adjuvant therapy with IVIG did not improve the in-hospital mortality rate or the need for mechanical ventilation in patients with severe COVID-19. In contrast, the application of IVIG was related to a longer hospital stay.

Introduction

Coronavirus disease 2019 (COVID-19) is a prevalent respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although most patients with COVID-19 suffer mild symptoms, approximately 15% of COVID-19 patients progress to severe pneumonia, and 5% develop acute respiratory distress syndrome [1, 2]. The treatments for COVID-19 include antiviral therapy and symptomatic therapy. Many clinical studies are under way to explore the effectiveness of antiviral drugs for the treatment of COVID-19. However, there is currently no sufficient evidence to confirm the effectiveness of antiviral therapies [3, 4].

COVID-19 can cause a host inflammatory responses. As the disease progresses, the levels of systemic proinflammatory cytokines and biomarkers increase, an increase that is correlated with poor prognosis. Such phenomena indicate that the inflammatory storm caused by viral invasion plays an important role in disease progression. Regulation of the immune response with immunomodulatory drugs may prevent the occurrence of organ dysfunction. Intravenous immunoglobulin (IVIG) is a nonspecific immunomodulator. Continuous infusion of IVIG increases plasma IgG levels and effectively neutralizes respiratory pathogens, thereby promoting disease recovery and shortening the disease course. IVIG

improves the body's defense system, blocks the related receptors in target cells, and prevents pathogens from further damaging target cells [5]. In addition, IVIG affects the differentiation and maturation of lymphocytes, blocks the normal immune response of leukocytes, inhibits the production of inflammatory factors, and reduces inflammatory injury [6–8]. Based on the clinical efficacy of IVIG in other viral diseases, some clinicians speculate that IVIG may improve the prognosis of patients with COVID-19 [6, 9–10]. Although the trial version guidelines issued by the National Health Commission and Administration of Traditional Chinese Medicine proposes that IVIG can be considered for severely and critically ill patients with COVID-19, the role of IVIG in the treatment of COVID-19 remains controversial. Therefore, this study retrospectively analyzed the correlation between the application of IVIG adjuvant therapy and the prognosis of patients with severe COVID-19 and explored the therapeutic effect of IVIG.

Methods

Research design and subjects

This single-center retrospective cohort study was conducted in the Respiratory and Critical Care Unit of Dabie Mountain Regional Medical Center under the jurisdiction of the Shandong Medical Team. Dabie Mountain Regional Medical Center is a designated hospital in Huanggang City (Hubei Province, China) for the treatment of patients with confirmed COVID-19. All patients were transferred from other hospitals, and laboratory confirmation was performed by their local health bureau in accordance with the diagnostic standards of the National Health Commission [11]. We retrospectively analyzed patients with severe COVID-19 newly admitted between January 28 and February 25, 2020. According to the World Health Organization (WHO) interim guidance [12], severe COVID-19 was defined as having one of the following three conditions: respiratory rate ≥ 30 breaths/min, severe respiratory distress, or peripheral capillary oxygen saturation (SpO₂) $\leq 93\%$ when inhaling room air. The identification of critically ill patients was achieved by reviewing all available electronic data such as admission records, nursing records, and treatment logs.

Inclusion and exclusion criteria

All adult patients with severe COVID-19 were screened. The exclusion criteria for the study included age < 18 years, unstable tumor or blood disease, pregnancy, multiple injuries, craniocerebral trauma, mechanical ventilation on admission, and lack of important data.

Data collection

We collected the patients' information, including age, sex, concomitant diseases (including hypertension, diabetes, coronary heart disease, chronic obstructive pulmonary disease (COPD), and cerebrovascular disease), the time from onset to admission, the highest body temperature before admission, laboratory examination indicators at admission (including white blood cell count, lymphocyte count, platelet count, alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine, prothrombin time (PT), and D-dimer), the use of glucocorticoids (including methylprednisone, dexamethasone and

hydrocortisone), and the use of intravenous immunoglobulin (IVIG). The prognostic indicators of the patients were also collected, including hospital mortality, the use of mechanical ventilation and the length of hospital stay. All data were collected by two investigators (Hao Hao and Meng Xianqing) separately. If there was any deviation in agreement, a third investigator (Kong Li) made the final decision. All missing continuous variables were replaced by the median or mean. The primary prognostic endpoint was the composite end point, including death or the use of mechanical ventilation. The secondary prognostic endpoint was the length of hospital stay.

Statistical analysis

Statistical analysis was performed using SPSS 26.0. The data that fit a normal distribution are expressed as the mean $\pm$ standard deviation ($\bar{x} \pm s$), and comparisons between groups was performed using the t test. Non-normally distributed data are expressed as the median (quartile) (M (Q)) and were compared using a nonparametric test. Count data are expressed as the frequency and percentage, and comparisons between groups were performed using the chi-squared test. The correlation between IVIG and prognosis was examined using logistic regression analysis (the results are presented as the OR value and 95% C.I.). The correlation between IVIG and the length of hospital stay was examined using multivariate linear regression analysis. Two-tailed $P < 0.05$ indicated a statistically significant difference.

Results

From January 28 to February 25, 2020, a total of 285 patients with confirmed COVID-19 were treated in the Respiratory and Critical Care Unit of Dabie Mountain Regional Medical Center under the jurisdiction of the Shandong Medical Team. Among these patients, 113 (39.6%) were included in the present study. The research flow chart is shown in Fig. 1.

The comparison of baseline data is shown in Table 1. The age of the patients was 55.1 ± 14.2 years, and 52 (46%) patients were female. Among these patients, 39 (34.5%) suffered from comorbidities, including 26 (23.0%) with hypertension, 13 (11.5%) with diabetes, 7 (6.2%) with coronary heart disease, 6 (5.3%) with COPD, and 4 (3.5%) with cerebrovascular diseases. The maximum body temperature before admission was 38.5°C (37.7–39.0), and the time from onset to hospitalization was 7.0 days (5.0–10.0). Forty-seven patients (41.6%) received IVIG. Compared with patients who did not receive IVIG, fewer patients who received IVIG therapy had coronary heart disease [0 (0) vs 7 (10.6%), $P = 0.021$]. In addition, patients who received IVIG therapy had a higher body temperature [38.9 (38.2–39.0) vs 38.0 (37.5–38.8), $P = 0.002$] before hospital admission, a higher white blood cell count [7.45 (4.73–9.42) vs 5.00 (3.68–6.79), $P < 0.001$], a lower lymphocyte count [0.79 (0.62–1.21) vs 1.24 (0.90–1.75), $P < 0.001$], and a higher glutamate aminotransferase level [29.7 (18.0–47) vs 21.0 (14.2–29.2), $P = 0.008$]. More patients in the IVIG group used glucocorticoids [39 (83.0%) vs 18 (27.3%), $P < 0.001$]. In contrast, there were no statistically significant differences between the groups of patients in age, sex, comorbidities, concurrent hypertension, diabetes, COPD, cerebrovascular disease, platelet count, ALT level, serum creatinine level, PT level and D-dimer level.

Table 1
Demographic data and clinical characteristics of patients in the IVIG and non-IVIG groups

Parameter	Total n = 113	Non-IVIG n = 66	IVIG n = 47	P
Age	55.1 ± 14.2	55.3 ± 15.5	54.8 ± 12.4	0.865
Female	52 (46.0%)	32 (48.5%)	20 (42.6%)	0.533
Comorbidity	39 (34.5%)	23 (34.8%)	16 (34.0%)	0.929
Hypertension	26 (23.0%)	14 (21.2%)	12 (25.5%)	0.591
Diabetes	13 (11.5%)	6 (9.1%)	7 (14.9%)	0.341
Coronary heart disease	7 (6.2%)	7 (10.6%)	0 (0)	0.021
COPD	6 (5.3%)	5 (7.6%)	1 (2.1%)	0.203
Cerebrovascular disease	4 (3.5%)	4 (6.1%)	0 (0)	0.086
Onset time	7.0 (5.0–10.0)	7.0 (5.0–9.2)	7.0 (5.0–10.0)	0.268
Maximum body temperature	38.5 (37.8–39.0)	38.0 (37.5–38.8)	38.9 (38.2–39.0)	0.002
WBC	5.61 (4.09–8.04)	5.00 (3.68–6.79)	7.45 (4.73–9.42)	< 0.001
LYM	1.07 (0.72–1.51)	1.24 (0.90–1.75)	0.79 (0.62–1.21)	< 0.001
PLT	200.0 (153.0–256.0)	203.0 (149.8–252.2)	190.0 (159.0–257.0)	0.836
ALT	23.0 (16.5–37.2)	21.0 (14.2–29.2)	29.7 (18.0–47)	0.008
AST	21.0 (17.0–33.0)	20.6 (16.8–26.2)	22.0 (17.0–40.0)	0.287
Cr	78.1 ± 23.9	78.2 ± 24.3	78.8 ± 23.6	0.896
PT	44.6 ± 1.3	11.4 ± 1.2	11.9 ± 1.4	0.56
DD	192.0 (115.0–456.0)	182.5 (105.8–294.5)	216.0 (125.0–840.0)	0.249
GC	57 (50.4%)	18 (27.3%)	39 (83.0%)	< 0.001

Abbreviations: IVIG, intravenous immunoglobulin; COPD, chronic obstructive pulmonary disease; WBC, white blood cell; LYM, lymphocyte; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, serum creatinine; PT, prothrombin time; DD, D-dimer; GC, Glucocorticoid.

The outcome indicators are shown in Table 2. A total of 17 (15.0%) patients reached the composite end point, including 13 (11.5%) patients who died and 11 (9.7%) patients who received mechanical

ventilation. Compared with the non-IVIG group, more patients in the IVIG group reached the composite end point [12 (25.5%) vs 5 (7.6%), $P = 0.008$]. Specifically, an increased percentage of patients in the IVIG group died [9 (19.1%) vs 4 (6.1%), $P = 0.032$] or received mechanical ventilation [10 (21.3%) vs 1 (1.5%), $P < 0.001$].

Table 2
The effect of IVIG therapy on the primary and secondary prognostic endpoints

Parameter	Total n = 113	Non-IVIG n = 66	IVIG n = 47	P	P*
Composite end point	17 (15.0%)	5 (7.6%)	12 (25.5%)	0.008	0.167
Death	13 (11.5%)	4 (6.1%)	9 (19.1%)	0.032	-
Mechanical ventilation	11 (9.7%)	1 (1.5%)	10 (21.3%)	< 0.001	-
Length of hospital stay	20.0 (15.0–25.0)	16.0 (13.8–22.0)	23.0 (19.0–31.0)	< 0.001	0.041

* Corrected by age, sex, comorbidities, maximum body temperature, WBC, LYM, AST, PT, DD and use of glucocorticoids

The univariate analysis results are provided in Table 3. Several variables were statistically significant differences between patients who reached the prognostic endpoint and those who did not reach the prognostic endpoint; those variables were age [59.0 (52.0–73.5) vs 54.0 (45.2–62.0), $P = 0.042$], maximum body temperature [38.9 (38.2–39.4) vs 38.4 (37.6–39.0), $P = 0.041$], female [4 (23.5%) vs 48 (50.0%), $P = 0.044$], comorbidities [11 (64.7%) vs 28 (29.2%), $P = 0.004$], white blood cell count [8.43 (6.58–16.21) vs 5.28 (4.02–7.22), $P = 0.001$], lymphocyte count [36.0 (18.0–45.4) vs 20.6 (17.0–27.0), $P = 0.029$], AST level [36.0 (18.0–45.4) vs 20.6 (17.0–27.0), $P = 0.029$], PT (12.9 ± 1.6 vs 11.4 ± 1.2 , $P < 0.001$), D-dimer level [851.0 (217.0–9954.5) vs 172.0 (107.9–285.5), $P < 0.001$], use of glucocorticoids [14 (82.4%) vs 43 (44.8%), $P = 0.004$], and use of IVIG [12 (70.6%) vs 35 (36.5%), $P = 0.008$]. After adjusting for the above confounding factors, there was no statistically significant difference in the rate of reaching the composite end point between the IVIG group and the non-IVIG group (OR = 2.605, 95%CI 0.67–10.10, $P = 0.167$). Multivariate logistic regression analysis showed that the factors related to reaching the prognostic endpoint included comorbidities (OR = 4.187, 95%CI 1.14–15.41, $P = 0.031$), white blood cell count (OR = 1.18, 95%CI 1.06–1.31, $P = 0.003$), and PT (OR = 2.15, 95%CI 1.30–3.54, $P = 0.003$).

Table 3

Univariate analysis of the patients who reached the composite end point and the patients who failed to reach the composite end point

Parameter	Patients who reached the composite end point n = 96	Patients who failed to reach the composite end point n = 17	P
Age	54.0 (45.2–62.0)	59.0 (52.0–73.5)	0.042
Female	48 (50.0%)	4 (23.5%)	0.044
Comorbidity	28 (29.2%)	11 (64.7%)	0.004
Hypertension	19 (19.8%)	7 (41.2%)	0.053
Diabetes	9 (9.4%)	4 (23.5%)	0.092
Coronary heart disease	4 (4.2%)	3 (17.6%)	0.034
COPD	4 (4.2%)	2 (11.8%)	0.198
Cerebrovascular disease	2 (2.1%)	2 (11.8%)	0.046
Time of onset	7.0 (5.0–10.0)	7.0 (6.5–10.0)	0.499
Body temperature	38.4 (37.6–39.0)	38.9 (38.2–39.4)	0.041
WBC	5.28 (4.02–7.22)	8.43 (6.58–16.21)	0.001
LYM	1.12 (0.78–1.54)	0.67 (0.55–1.03)	0.001
PLT	201.0 (159.2–258.5)	191.0 (124.0–213.5)	0.086
ALT	23.0 (15.0–34.7)	29.7 (21.5–74.0)	0.065
AST	20.6 (17.0–27.0)	36.0 (18.0–45.4)	0.029
Cr	76.6 ± 22.2	88.6 ± 30.5	0.056
PT	11.4 ± 1.2	12.9 ± 1.6	< 0.001
DD	172.0 (107.9–285.5)	851.0 (217.0–9954.5)	< 0.001
GC	43 (44.8%)	14 (82.4%)	0.004
IVIG	35 (36.5%)	12 (70.6%)	0.008

Abbreviations: IVIG, intravenous immunoglobulin; COPD, chronic obstructive pulmonary disease; WBC, white blood cell; LYM, lymphocyte; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, serum creatinine; PT, prothrombin time; DD, D-dimer; GC, Glucocorticoid.

Analysis of the secondary prognostic endpoints showed that the length of hospital stay was 20.0 days (15.0–25.0). Compared with the non-IVIG group, patients in the IVIG group had a longer hospital stay [23.0 days (19.0–31.0) vs 16.0 (13.8–22.0), $P < 0.001$]. After adjusting for confounding factors including age, sex, maximum body temperature, comorbidities, AST, hormones, WBC, D-dimer and PT, it was found that the patients in the IVIG group had a significantly longer hospital stay compared with that for the patients in the non-IVIG group ($P = 0.041$) (Table 2).

Discussion

This study explored the correlation between the application of IVIG and the prognosis of patients with severe COVID-19. The results showed that 41.6% of critically ill patients received IVIG therapy. Approximately 25.5% of the patients in the IVIG group reached the composite end point, a percentage greater than that in the non-IVIG group. However, multivariate logistic analysis showed that the use of IVIG was not correlated with the poor prognosis of patients with severe COVID-19. The high mortality rate in the IVIG group might be related to the lower lymphocyte count, higher white blood cell count and maximum body temperature. According to the results of previous studies [13–15], these factors were all related to the poor prognosis of COVID-19 patients, suggesting that the condition of the patients in the IVIG group was more severe.

Although certain interim guidelines recommend IVIG adjuvant therapy for patients with severe COVID-19, there is a lack of effective evidence-based proof supporting this treatment. Xie et al. [16] retrospectively studied 58 patients with severe or critical COVID-19, all of whom were treated with IVIG. The study found that the administration of IVIG within 48 h was related to a reduction in 28-day mortality, length of hospital stay and time in the ICU. In the study conducted by Xie et al., the overall 28-day mortality rate was 39.6%, which was much higher than the mortality rate in our study (11.5%). Such phenomenon indicates that the condition of the patients included in Xie's study was more severe. Shao et al. [17] conducted a multicenter retrospective cohort study that included 325 patients with confirmed severe or critical COVID-19. Among the 325 patients, 222 (68%) had severe COVID-19, and 103 (32%) had critical COVID-19. No significant differences were found in the 28-day mortality rate and 60-day mortality rate between the IVIG group and the non-IVIG group. After adjusting for baseline data such as age, sex, body temperature, comorbidities and WBC, it was found that the use of IVIG was related to a decrease in the 28-day mortality rate. That finding was different from the results of our study. However, subgroup analysis in the study by Shao et al. showed that IVIG treatment was only able to significantly reduce the 28-day mortality rate in critically ill patients (defined by one of the following three criteria: a, respiratory failure requiring mechanical ventilation; b, shock; and c, multiple organ failure requiring ICU treatment). In severely ill patients (defined as having one of the following three conditions: a, respiratory rate ≥ 30 breaths/min; b, resting state $SpO_2 \leq 90\%$; and c, $PaO_2/FiO_2 \leq 300$ mmHg), the use of IVIG was not related to a decrease in the 28-day mortality rate. The severely ill patients included in the study by Shao et al. were similar to those included in our study, and the mortality rate was also similar to that in our study. In the study conducted by Xie et al. [16], severely ill patients in the IVIG group had a longer hospital stay than did those in the non-IVIG group [22.0 (18.0–30.0) vs 15.0 (13.0–22.0), $P < 0.001$]. That conclusion

was consistent with the results of our study. The length of hospital stay was similar between the two studies.

IVIG has been used for the treatment of severe viral infections, bacterial infections and sepsis. One study has proved the clinical efficacy of IVIG [18], especially in viral infectious diseases. However, other studies have failed to confirm the clinical efficacy of IVIG [19], leading to a controversy regarding the application of IVIG in acute respiratory viral infectious diseases. Similar discrepancies have occurred among COVID-19 studies, possibly related to the severity of the disease, the timing and dosage of IVIG application, and the duration of the inflammatory response caused by the disease. An excessive inflammatory response is one of the main pathological changes in COVID-19 patients. A severe cytokine storm has been found to be related to increased mortality in severely ill patients. Like immunoglobulins, glucocorticoids are also used as nonspecific immunomodulatory drugs for adjuvant treatment of COVID-19 patients [20]. A large-scale randomized open label study in the United Kingdom showed that dexamethasone reduced the 28-day mortality rate in patients who received invasive mechanical ventilation (29.3% vs 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) or patients who received oxygen therapy alone (23.3% vs 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) [21]. However, dexamethasone was not beneficial to COVID-19 patients who did not require respiratory support (17.8% vs 14.0%; rate ratio, 1.19; 95% CI, 0.91 to 1.55). The results of the above studies indicate that nonspecific immunomodulatory therapies are more beneficial to critically ill patients. This conjecture needs to be confirmed by well-designed randomized controlled trials.

Our study had a number of limitations. First, this was a single-center retrospective cohort study that lacked sufficient representativeness and could not clarify any causal relationship. Second, the timing and dose of IVIG were not considered, although most patients received 0.5 g/kg/d recommend by the Chinese guidelines. Third, many confounding factors that might affect the prognosis of patients (such as PaO₂/FiO₂, troponin, and imaging changes) were not examined. Fourth, due to the clinical workload and the situation at the time, data such as virus shedding time and immunoglobulin-related complications were not collected. In the future, prospective studies are needed to explore the role of IVIG in COVID-19.

Conclusion

IVIG is not related to the in-hospital mortality rate and the use of mechanical ventilation in patients with severe COVID-19. These relationships need to be confirmed by prospective randomized controlled studies.

Abbreviations

COVID-19: Coronavirus disease 2019; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; IVIG: Intravenous immunoglobulin; COPD, chronic obstructive pulmonary disease; WBC, white blood cell; LYM, lymphocyte; PLT, platelet; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, serum creatinine; PT, prothrombin time; DD, D-dimer; GC, Glucocorticoid.

Declarations

Acknowledgements

Not applicable.

Author contributions

HH, LZ and XHJ conceived and designed the study. HH, XQM and LK collected clinical data. XH, LT drafted original manuscript. XH, LT, YTX, FHZ and XBD analyzed the data. All authors revised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (81704028, 81974545) and China Postdoctoral Science Foundation (2020M670045ZX).

Availability of data and materials

All data supporting the conclusions of this article are included in this published article.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine (KY-2020-002), and informed consent was waived.

Consent for publication

Not applicable.

Conflicts of interest

All authors declare that they have no conflicts of interest.

References

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020; 395, 497–506.
2. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med*. 2020; 8(4): 420-422.
3. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2020; NEJMoa2023184.
4. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med*. 2020 May 7; 382(19):1787-1799.

5. Takashi T, Hiroki M, Kiyohide F, Hideo Y. Intravenous immunoglobulin and mortality in pneumonia patients with septic shock: an observational nationwide study. *Clin Infect Diseases*. 2015; 61 (3):385–92.
6. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, et al. Hyperimmune IV Immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 in-fluenza A (H1N1) infection. *Chest*. 2013; 144 (2):464–73.
7. Diebel LN, Liberati DM, Diglio CA, Brown WJ. Immunoglobulin a modulates inflam-matory responses in an in vitro model of pneumonia. *J Trauma Injury Infect Crit Care*. 2005; 1099–106.
8. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglob-ulin in the prevention of pneumonia in patients with common variable immun-odeficiency. *J Allergy Clin Immunol*. 2002; 109 (6):1001–4.
9. Chong PY, Chui P, Ling AE, Franks TJ, Tai DY, Leo YS, et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. *Arch Pathol Lab Med*. 2004; 128: 195–204.
10. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med*. 2006; 145: 599–609.
11. National health commission of People’s Republic of China. Interim guidance of COVID-19. <http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml>. Accessed 23 Jan 2020.
12. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. 2020. <https://apps.who.int/iris/handle/10665/331446>. Accessed 18 Mar 2020.
13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020; 395:1054-62.
14. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 2020 Jul 1; 180(7):934-943.
15. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol*. 2020 Jul 1; 5(7):802-810.
16. Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. *Journal of Infection*. 2020; 318-356.
17. Shao Z, Feng Y, Zhong L, Xie Q, Lei M, Liu Z, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. *Clin Transl Immunology*. 2020; 9(10):e1192.
18. Berlot G, Vassallo MC, Busetto N, Nieto Yabar M, Istrati T, Baronio S, et al. Effects of the timing of administration of IgM- and IgA-enriched intravenous polyclonal immunoglobulins on the outcome of septic shock patients. *Ann Intensive Care*. 2018; 8(1):122.

19. Lai ST. Treatment of severe acute respiratory syndrome. *Eur J Clin Microbiol Infect Dis*. 2005; 24: 583–591.
20. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-immunomodulatory therapy in COVID-19. *Drugs*. 2020; 80: 1267-1292.
21. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med*. 2020 Jul 17; NEJMoa2021436.

Figures

Figure 1

The research flow chart